论文部分内容阅读
目的:观察恩替卡韦联合大黄蛰虫丸治疗慢性乙型病毒性肝炎(CHB)对肝纤维化指标的影响。方法:140例CHB患者随机分为治疗组与对照组,分别给予恩替卡韦+大黄蛰虫丸、恩替卡韦治疗12个月。观察2组肝功能指标、肝纤维化血清学指标、不良反应发生情况。结果:治疗组与对照组的丙氨酸氨基转移酶复常率分别为88.9%、73.5%(P>0.05),总胆红素复常率分别为88.2%、91.7%%(P>0.05);治疗组治疗后玻璃酸、层黏蛋白、Ⅲ型前胶原、Ⅳ型胶原肽的下降幅度均明显大于对照组(P<0.05);治疗组有2例发生了轻度的药品不良反应。结论:恩替卡韦联合大黄蛰虫丸治疗更有利于阻滞或逆转肝纤维化的形成和发展。
Objective: To observe the effect of entecavir combined with rhubarb and zhuang zhi pill in treatment of chronic hepatitis B (CHB) on liver fibrosis index. Methods: One hundred and forty patients with CHB were randomly divided into treatment group and control group. Entecavir + Rhubarb and Rhubarb were respectively administered for 12 months. Two groups of liver function indicators, serum fibrosis indicators, adverse reactions were observed. Results: The normal rates of alanine aminotransferase in treatment group and control group were 88.9% and 73.5% respectively (P> 0.05), and the rates of total bilirubin were 88.2% and 91.7% respectively (P0.05) . The decrease of hyaluronic acid, laminin, type Ⅲ procollagen and type Ⅳ collagen peptide in the treatment group were significantly greater than those in the control group (P <0.05). Two patients in the treatment group had mild adverse drug reaction. Conclusion: The treatment of entecavir combined with rhubarb and zhuang zhi pills is more beneficial to block or reverse the formation and development of hepatic fibrosis.